Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Lars Fruergaard Jørgensen

Wegovy maker Novo Nordisk’s chair and six other board members step down

Surprise shake-up follows row with majority shareholder, which seeks ‘extensive reconfiguration’

The Guardian - UK

With Novo Nordisk's CEO Out, Wall Street Wants an American Leader

With its stock plummeting over the past year, Novo Nordisk is waving goodbye to its top executive. What might the future hold for the weight-loss drug kingpin?

MarketBeat

Is Novo Nordisk Stock a Buy, Sell, or Hold as CEO Lars Fruergaard Jørgensen Resigns?

Novo Nordisk stock sinks as CEO Lars Fruergaard announces his resignation. Analysts are not happy with his departure but continue to see significant upside in NVO shares.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Novo Nordisk CEO steps down amid growing competition for weight loss drugs

Lars Fruergaard Jørgensen, who has led the pharmaceutical giant since 2017, joined the firm in 1991.

Euronews

Currency hedging and new U.S. factories: Novo Nordisk CFO thinks Wegovy maker can outmaneuver global trade wars

Novo Nordisk's CFO says the company is well-placed to respond to an escalation of the global trade war.

Fortune

Novo Nordisk cuts guidance as weight-loss drug market competition grows

Novo Nordisk shares jumped following stronger-than-expected first-quarter earnings, despite the company lowering its growth outlook for 2025 amid intensifying competition in the weight-loss drug markets.

Euronews

Novo Nordisk confident despite Trump tariff risk as sales of weight-loss jab soar

Europe’s biggest firm, whose sales of Wegovy almost doubled, feels it can ‘meet demands’ of US administration

The Guardian - UK

Read news from The Economist, FT, and more,
with one subscription

Biden Proposes Medicare, Medicaid Access For Popular Weight-Loss Drugs

The Biden Administration's proposal expands Medicare and Medicaid coverage for anti-obesity drugs, cutting costs for millions while addressing the obesity crisis.

Benzinga

Elon Musk and Bernie Sanders say they agree on one thing—cheaper Ozempic

Novo Nordisk is investing $30 billion to expand production, but middlemen are pocketing 74 cents of every dollar it makes in sales.

Fortune

Novo Nordisk CEO blames PBMs, insurers for Ozempic price tag - Roll Call

Senate HELP Chairman Bernie Sanders launches another salvo in drug pricing war, this one aimed at popular weight loss drugs.

Roll Call

Novo Nordisk CEO takes aim at U.S. health system in Ozempic testimony

Novo Nordisk's CEO said the complexities of the U.S. healtchare system prevented access to $1,349 Wegovy.

Fortune

Analysts say market forces will lower cost of obesity drugs - Roll Call

Hearing on weight loss drug prices will feature CEO of Novo Nordisk and comes after threats to subpoena company executives.

Roll Call

Novo Nordisk CEO to face off with Bernie Sanders over 1,300% Ozempic markup in U.S.

Novo's Danish CEO Lars Fruergaard Jørgensen will face the U.S. Senate in September to defend Wegovy's and Ozempic's eye-watering prices.

Fortune

Wegovy maker Novo Nordisk could make prices flexible—without cutting them—to persuade more health systems to cover the weight-loss drugs

Weight-loss drug Wegovy faces high demand, limited supply, and tricky health care systems to navigate.

Fortune

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

Revealed: obesity jab maker discussed targeting benefit claimants with UK government

Drug firm Novo Nordisk proposed singling out those most likely to return to work with its weight-loss injection

Fortune

Germany considers banning Ozempic exports, including to U.S.

Germany exports Ozempic to the EU and the U.S., Karl Broich, president of the German Federal Institute for Drugs and Medical Devices, told Der Spiegel.

Fortune

Novo Nordisk threatens to expand in US in row over EU rules

Novo Nordisk's CEO doesn't like proposed new EU rules that would cut the period for which drugmakers enjoy exclusivity for their products from 10 years to eight years.

StockNews.com

1 Pharma Stock That Could Help You Become a Millionaire

Prominent pharma player Novo Nordisk (NVO) posted solid revenue and earnings growth in fiscal 2022. The company’s long-term growth is expected to be spearheaded by its immensely popular GLP-1 drug Wegovy. Given the potential of its current portfolio of drugs and drugs under research, investing in this stock could be…

Get all your
news in one place.

100’s of premium titles.
One news app.

People

Dipanjan BanchurSince

Lars Fruergaard Jørgensen

18 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Medical Pharmaceuticals

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.